COMMUNIQUÉS West-GlobeNewswire
-
GUERBET : Calendrier financier de l’exercice 2026
19/11/2025 -
Curium Announces First Commercial Doses of Diagnostic Radiopharmaceutical in Czech Republic and Slovakia for Patients with Prostate Cancer
19/11/2025 -
Sanara MedTech to Participate in the Piper Sandler 37th Annual Healthcare Conference on December 3rd
19/11/2025 -
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
19/11/2025 -
Avicanna Announces Pre-Clinical Data Supporting Enhanced Absorption and Patent Filing for Novel Oral Delivery Platform
19/11/2025 -
Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
19/11/2025 -
LUKE and Asset Health Forge National Partnership to Advance Human Flourishing for America’s Heroes
19/11/2025 -
Nxera Introduces Employee Stock Ownership Plan (J-ESOP) for Employees Residing in Japan
19/11/2025 -
BioPorto Interim Result for the Third Quarter of 2025 – Continued progress and continued NGAL sales growth
19/11/2025 -
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
19/11/2025 -
European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
19/11/2025 -
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
18/11/2025 -
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
18/11/2025 -
Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease
18/11/2025 -
SI-BONE To Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025
18/11/2025 -
BBOT to Participate in Upcoming December Investor Healthcare Conferences
18/11/2025 -
Solana Company Reports Third Quarter 2025 Financial Results
18/11/2025 -
Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer
18/11/2025 -
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
18/11/2025
Pages